Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.14 Bil PE Ratio: 17.29 PB Ratio: 2.38 GF Score: 88/100

Incyte Corp Call to Discuss Pemigatinib Development Update from European Society for Medical Oncology Transcript

Sep 27, 2019 / 03:00PM GMT
Release Date Price: $72.82 (-1.27%)
Operator

Greetings and welcome to the Incyte Corp. conference call and webcast from EMSO (sic) [ESMO] 2019. (Operator Instructions) It is now my pleasure to introduce your host, Mike Booth, Head of Investor Relations. Thank you. You may begin.

Michael Booth
Incyte Corporation - Divisional VP of IR & Corporate Social Responsibility

Thank you, Donna. Good afternoon from Barcelona and good morning to those of you joining us from the U.S. Welcome to our conference call and webcast to discuss the pemigatinib data that was just shown here at ESMO as well as our development plans and the potential opportunity for the product candidate. The slides used today -- used in today's webcast are available for download on the Investors section of incyte.com as are the full data slides as presented in Barcelona earlier this afternoon.

I'm joined on the call today by Hervé and Steven. Hervé will begin with a few opening remarks before Steven provides us with some important context on the disease of cholangiocarcinoma, the evident unmet medical need and the rationale and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot